IBRX vs UBER · rev $113.3M vs P/E 18, rev $52.02B
Immunitybio Inc (IBRX) versus Uber Technologies Inc (UBER) — a side-by-side from cached financials, not a winner call.
Immunitybio Inc (IBRX) is a biotechnology company listed on US.
Uber Technologies Inc (UBER) is a software - application company listed on NYSE. It is led by Dara Khosrowshahi.
Latest reported IBRX revenue for 2025-12-31 was $113.3M. Net income was -$351.4M. Revenue was up 668.3% from 2024-12-31 to 2025-12-31. IBRX currently screens at market cap $7.88B.
Latest reported UBER revenue for 2025-12-31 was $52.02B. Net income was $10.05B. Revenue was up 18.3% from 2024-12-31 to 2025-12-31. UBER currently screens at market cap $144.34B and trailing P/E 17.6.
IBRX currently screens at market cap $7.88B. UBER currently screens at market cap $144.34B and trailing P/E 17.6.
Not investment advice. Open the IBRX and UBER stock pages for the full models.
Not investment advice.